Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Nicholas, Lydon"'
Autor:
Joseph L. Kim, Oleg Schmidt-Kittler, Yemarshet K. Gebreyohannes, Timothy Guzi, Kevin J. Wilson, Alison J. Davis, Alexandra K. Gardino, Adam Shutes, Christoph Lengauer, Lucian DiPietro, Stephen D. Miller, Brian L. Hodous, Yulian Zhang, Doug Wilson, Timothy LaBranche, Nicholas Lydon, Michael Heinrich, Nancy Kohl, Patrick Schöffski, Natasja Brooijmans, Agnieszka Wozniak, Erica Evans, Xing Julia Zhu, Daniel J. DeAngelo, Andy Boral, Beni B. Wolf
Publikováno v:
Science Translational Medicine. 9
Targeting oncogenic kinase drivers with small-molecule inhibitors can have marked therapeutic benefit, especially when administered to an appropriate genomically defined patient population. Cancer genomics and mechanistic studies have revealed that h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb6e3ad5639cb0b7a03fc75164a59dec
https://doi.org/10.1126/scitranslmed.aao1690
https://doi.org/10.1126/scitranslmed.aao1690
Autor:
Erica K, Evans, Alexandra K, Gardino, Joseph L, Kim, Brian L, Hodous, Adam, Shutes, Alison, Davis, Xing Julia, Zhu, Oleg, Schmidt-Kittler, Doug, Wilson, Kevin, Wilson, Lucian, DiPietro, Yulian, Zhang, Natasja, Brooijmans, Timothy P, LaBranche, Agnieszka, Wozniak, Yemarshet K, Gebreyohannes, Patrick, Schöffski, Michael C, Heinrich, Daniel J, DeAngelo, Stephen, Miller, Beni, Wolf, Nancy, Kohl, Timothy, Guzi, Nicholas, Lydon, Andy, Boral, Christoph, Lengauer
Publikováno v:
Science translational medicine. 9(414)
Targeting oncogenic kinase drivers with small-molecule inhibitors can have marked therapeutic benefit, especially when administered to an appropriate genomically defined patient population. Cancer genomics and mechanistic studies have revealed that h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::44c23e872b4ee8effe4e9b9a2cdce3de
https://pubmed.ncbi.nlm.nih.gov/30023395
https://pubmed.ncbi.nlm.nih.gov/30023395
Publikováno v:
Journal of Medicinal Chemistry. 39:2285-2292
Using a pharmacophore model for ATP-competitive inhibitors interacting with the active site of the EGF-R protein tyrosine kinase (PTK), 4-(phenylamino)-7H-pyrrolo[2,3-d]pyrimidines have been identified as a novel class of potent EGF-R protein tyrosin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5649c714933557014d2beada688d4dd2
https://doi.org/10.1021/jm960118j
https://doi.org/10.1021/jm960118j
Autor:
Catherine Favre, Gail F. Seelig, Sylvie Benureau, Odile Neyret, Nicholas Lydon, Sylvie Bove, Alan M. Levine, Tatanahalli L. Nagabhushan, Paul P. Trotta
Publikováno v:
Biochemistry. 24:4131-4141
A panel of five monoclonal antibodies, designated U1-U5, produced by murine hybridoma clones has been raised to recombinant interferon (IFN) alpha-2, and one monoclonal antibody, designated U6, has been raised to a mixture of cyanogen bromide fragmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e356c78bdeeb52cf2b53c7405c8bc705
https://doi.org/10.1021/bi00336a048
https://doi.org/10.1021/bi00336a048
Autor:
Druker BJ; Knight Cancer Institute at Oregon Health & Science University, Portland, Oregon, and a Howard Hughes Medical Institute investigator. He shared the 2012 Japan Prize with Janet Rowley and Nicholas Lydon.
Publikováno v:
Nature [Nature] 2014 Jan 23; Vol. 505 (7484), pp. 484.